series-c-plus
Stage
2012
Founded
1
Investors
About
Prothena is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and rare peripheral amyloid diseases by targeting protein dysregulation.
Explore Prothena's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.